Current stage-Inflammatory breast cancer - Page 2 of 3 Posts on Medivizor
Navigation Menu

Current stage-Inflammatory breast cancer Posts on Medivizor

A new treatment option for breast cancer

A new treatment option for breast cancer

Posted by on Sep 23, 2013 in Breast cancer | 1 comment

In a nutshell This phase II clinical trial examined the safety and efficacy of adding a drug called rh-endostatin (Endostar) to chemotherapy in breast cancer patients. Some background Cancer cells need blood supply in order to grow. As cancer grows, it forms its own blood vessels, a process called angiogenesis. Therefore, anti-angiogenesis...

Read More

Evaluating quality of life in overweight and obese patients with breast cancer who undergo radiotherapy

Posted by on Aug 31, 2013 in Breast cancer | 0 comments

In a nutshell This study evaluated whether the Body Mass Index (BMI) influences the quality of life of breast cancer patients treated with radiotherapy.  Some background The Body Mass Index (BMI) is a weight to height ratio calculated by dividing a person’s weight in kilograms to their square of height in meters. A normal BMI ranges...

Read More

Tamoxifen reduces the risk of contralateral breast cancer in women with BRCA1 or BRCA2

Posted by on Aug 25, 2013 in Breast cancer | 0 comments

In a nutshell This study examined whether tamoxifen (nolvadex) can reduce the risk of contralateral breast cancer in women diagnosed with breast cancer and the BRCA1 or BRCA2 genetic mutation. Some background The BRCA1 and BRCA2 genetic mutations are associated with a high risk of developing breast cancer. While prophylactic mastectomies (a...

Read More

Reducing side effects of ixabepilone by reducing dosage

Posted by on Aug 19, 2013 in Breast cancer | 0 comments

In a nutshell In this study researchers reviewed the adverse effects of the chemotherapy drug ixabepilone for patients with metastatic breast cancer and how these can be managed by reducing the dosage. Some background Ixabepilone (Ixempra) is a chemotherapy drug approved by the U.S. FDA as treatment for metastatic breast cancer (breast cancer that...

Read More

Epoetin alfa improves anemia associated with chemotherapy in breast cancer patients

Posted by on Jul 27, 2013 in Breast cancer | 0 comments

In a nutshell In this study, researchers examined the effect of epoetin alfa (Epogen; Procrit) on anemia (low count of red blood cells) caused by chemotherapy in breast cancer patients. Some background Breast cancer is caused by a defect that makes some breast cancer cells grow and multiply rapidly. One of the treatment options for patients with...

Read More

Phase II clinical trial testing the safety and efficacy of adding entinostat to exemestane therapy in hormone-resistant breast cancer patients

Posted by on Jun 5, 2013 in Breast cancer | 0 comments

In a nutshell This phase II clinical trial tested whether a new drug, entinostat, can work in concert with exemestane (a hormone therapy drug), to fight breast cancer that no longer responds to hormone therapy alone. Some background Some breast cancers need estrogen (a female sex hormone) to grow. These breast cancer cells respond to estrogen via...

Read More

The pathways followed by doctors in the diagnosis and treatment of recurring and metastatic breast cancer

Posted by on Mar 11, 2013 in Breast cancer | 0 comments

This paper evaluates the process health care professionals follow to diagnose a cancer that reoccurs in the same location as a previous cancer (locally recurrent), or a cancer that has spread (metastasized). Despite earlier detection and improved treatment options for breast cancer, it is still the leading cause of cancer related deaths in...

Read More

Bosutinib: a new drug that increases progression free survival in patients with locally advanced or metastatic breast cancer

Posted by on Mar 11, 2013 in Breast cancer | 0 comments

In a nutshell This paper presents the results of a clinical study which looked at the use of a new drug called Bosutinib (Bosulif) for the treatment of breast cancers diagnosed as being stage III or IV. In patients previously treated with chemotherapy, Bosutinib showed promising efficacy in delaying cancer progression. Some background Locally...

Read More

Phase I trial to determine the safety of a new anti-cancer drug: PD 0332991

Posted by on Mar 11, 2013 in Breast cancer | 0 comments

In a nutshell This article presents the results from the first human trial of PD 0332991, a new anti-cancer drug. The main objective of the study was to determine the safety and recommended dose for further testing. Results warrant further studies and revealed that neutropenia (low white cell count) was the main side effect. Some background Cells...

Read More